-+ 0.00%
-+ 0.00%
-+ 0.00%

Lexeo Therapeutics Announces Interim Data From Its Ongoing HEROIC-PKP2 Phase I/II Clinical Trial Of LX2020 For Treatment Of PKP2 Arrhythmogenic Cardiomyopathy; Across Ten Participants, Including Nine With At Least 12 Months Of Follow-up, Treatment With LX2020 Was Generally Well Tolerated

Benzinga·11/16/2026 12:07:41
Listen to the news

Across ten participants, including nine with at least 12 months of follow-up, treatment with LX2020 was generally well tolerated and associated with clinically meaningful reductions in arrhythmia burden, including non-sustained ventricular tachycardia (NSVT) and premature ventricular contractions (PVC), as well as improvement in measures of right ventricular function and patient-reported symptoms. Lexeo is now designing a pivotal study with NSVT as a primary surrogate endpoint to support potential accelerated approval. The final study design including the statistical analysis plan and confirmatory strategy remains subject to future discussions with the FDA.

LX2020 Interim Update

Ten participants have been dosed in the HEROIC-PKP2 Phase I/II clinical trial, including three participants in Cohort 1 at the low dose (2×1013 vg/kg) and seven participants in Cohorts 2 and 3 at the high dose (6×1013 vg/kg). As of the October 15, 2026 data cutoff date, nine of ten participants reached at least 12 months of follow-up, with the remaining participant reaching nine months of follow-up. Safety and efficacy data are summarized for all ten participants at latest assessment.